A collaboration between haematology specialists, Accelerating Clinical Trials Ltd (ACT) and Dendrite Clinical Systems, has resulted in the roll-out of the 'MyeCare' UK Acute Myeloid Leukaemia (AML) Registry.
If you do one thing today then please listen to the following podcast.
The evening of the 1st of October marked a special occasion in the history of Accelerating Clinical Trials Ltd (ACT).
ACT to Attend ASH 2024: Advancing Blood Cancer Research Together
With support from Cure Leukaemia and NHSBT, ACT has been established as a commercial clinical trials delivery organisation with the aim of developing new treatments for blood cancers in the UK. ACT works with two networks of established and successful…
We welcome Lord O’Shaughnessy’s landmark report highlighting the importance of developing innovative models if the UK is to maintain global leadership in clinical trial delivery.
